Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases with significant unmet medical needs. The company’s primary focus is on rare conditions such as Duchenne muscular dystrophy (DMD), for which it has developed Agamree (vamorolone), a first-in-class dissociative steroid offering an alternative to traditional corticosteroids. This flagship product has received regulatory approval for the treatment of DMD in multiple regions, including the United States, European Union, and United Kingdom, underscoring its global presence. Santhera also maintains a clinical pipeline addressing other rare pulmonary disorders, further cementing its specialized role within the pharmaceutical sector. By targeting diseases that lack effective treatment options, Santhera Pharmaceuticals Holding AG plays a crucial role in addressing gaps in the orphan drug market, impacting patients, healthcare providers, and the broader pharmaceutical industry with its commitment to innovation in rare disease therapeutics.